Contemporary management of diabetic retinopathy in Canada: From guidelines to algorithm guidance

Ophthalmologica

Volumn 231, Issue 1, 2013, Pages 2-15

  Hooper, Philip ^a,i   Boucher, Marie Carole ^b   Colleaux, Kevin ^c   Cruess, Alan ^d   Greve, Mark ^e   Lam, Wai Ching ^f   Shortt, Stanley ^g   Tourville, Eric ^h  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITÉ LAVAL   (Canada)

ⁱ ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Treatment algorithms

Indexed keywords

STEROID; VASCULOTROPIN INHIBITOR;

ALGORITHM; ARTICLE; CANADA; CLINICAL PRACTICE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; FOLLOW UP; HUMAN; LASER COAGULATION; PRACTICE GUIDELINE; PREGNANCY; PROLIFERATIVE RETINOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINOPATHY; VITRECTOMY; AGE RELATED MACULAR DEGENERATION; CARDIOVASCULAR DISEASE; CENTRAL MACULAR THICKNESS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; HEALTH PROGRAM; LOW LEVEL LASER THERAPY; MACULAR EDEMA; MANAGED CARE; MEDICAL DECISION MAKING; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RETREATMENT; SCREENING TEST; TELEOPHTHALMOLOGY; TREATMENT DURATION; VISUAL ACUITY;

ALGORITHMS; CANADA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; MACULAR DEGENERATION; MACULAR EDEMA; MALE; OPHTHALMOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; SOCIETIES, MEDICAL;

EID: 84898420138     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000354548     Document Type: Article

References (41)

1. Hooper P, Boucher MC, Cruess A, et al: Canadian Ophthalmological Society evidencebased clinical practice guidelines for the management of diabetic retinopathy. Can J Ophthalmol 2012; 47(2 suppl):S1-S30.
2. Massin P, Bandello F, Garweg JG, et al: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.
3. Nguyen QD, Brown DM, Marcus DM, et al, RISE and RIDE Research Group: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
4. Nguyen QD, Shah SM, Khwaja AA, et al: Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
5. Mitchell P, Bandello F, Schmidt-Erfurth U, et al: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
6. Elman MJ, Aiello LP, Beck RW, et al, Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.
7. Elman MJ, Qin H, Aiello LP, Beck RW, et al, Diabetic Retinopathy Clinical Research Network: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312-2318.
8. Michaelides M, Kaines A, Hamilton RD, et al: A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078-1086.
9. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Arch Ophthalmol 1985; 103: 1796-1806.
10. Early Treatment Diabetic Retinopathy Study Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Phthalmology 1987; 94: 761-774.
11. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/ grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1449.
12. Campochiaro PA, Brown DM, Pearson A: Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125-2132.
13. Haller JA, Kuppermann BD, Blumenkranz MD, et al: Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128: 289-296.
14. Kimura T, Kiryu J, Nishiwaki H, et al: Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema. Retina 2005; 25: 454-461. (Pubitemid 40791883)
15. Stefaniotou M, Aspiotis M, Kalogeropoulos C, et al: Vitrectomy results for diffuse diabetic macular edema with and without inner limiting membrane removal. Eur J Ophthalmol 2004; 14: 137-143. (Pubitemid 38620466)
16. Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B: Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol 2005; 140: 295-301.
17. Yanyali A, Horozoglu F, Celik E, Ercalik Y, Nohutcu AF: Pars plana vitrectomy and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol 2006; 16: 573-581. (Pubitemid 44859666)
18. Thomas D, Bunce C, Moorman C, Laidlaw DA: A randomised controlled feasibility trial of vitrectomy vs. laser for diabetic macular oedema. Br J Ophthalmol 2005; 89: 81-86. (Pubitemid 40040244)
19. Patel JI, Hykin PG, Schadt M, et al: Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs. macular argon photocoagulation. Eye (Lond) 2006; 20: 873-881. (Pubitemid 44210178)
20. Kumar A, Sinha S, Azad R, Sharma YR, Vohra R: Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2007; 245: 360-368. (Pubitemid 46403996)
21. Yanyali A, Nohutcu AF, Horozoglu F, Celik E: Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 2005; 139: 795-801. (Pubitemid 40614763)
22. Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, et al: Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117: 1087-1093.
23. Bandello F, Cunha-Vaz J, Chong NV, et al: New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 2012; 26: 485-493.
24. Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy. Clinical applications of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981; 88: 583-600.
25. Early Treatment Diabetic Retinopathy Study Research Group: Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report No 19. Arch Ophthalmol 1995; 113: 1144-1155.
26. Brucker AJ, Qin H, Antoszyk AN, et al: Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009; 127: 132-40.
27. Vernon SA, Bhagey J, Boraik M, El-Defrawy H: Long-term review of driving potential following bilateral panretinal photocoagulation for proliferative diabetic retinopathy. Diabet Med 2009; 26: 97-99.
28. Adamis AP, Miller JW, Bernal MT, et al: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450. (Pubitemid 24307211)
29. Gaucher D, Fortunato P, LeCleire-Collet A, et al: Spontaneous resolution of macular edema after panretinal photocoagulation in florid proliferative diabetic retinopathy. Retina 2009; 29: 1282-1288.
30. Cunningham ET Jr, Adamis AP, Altaweel M, et al: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
31. Tonello M, Costra RA, Almeida FO, Barbosa JC, Scott IU, Jorge R: Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86: 385-389.
32. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H: Bevacizumab- augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18: 263-269. (Pubitemid 351692187)
33. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS: Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012; 130: 1145-1152.
34. Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM: Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina 2009; 29: 1134-1140.
35. Googe J, Brucker AJ, Bressler NM, et al, Diabetic Retinopathy Clinical Research Network: Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/ grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011; 31: 1009-1027.
36. Diabetic Retinopathy Vitrectomy Study Research Group: Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 1985; 103: 1644-1652.
37. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM: Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009; 19: 848-852.
38. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR: Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 785-791.
39. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G: Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 2008; 246: 837-842.
40. Ishikawa K, Honda S, Tsukahara Y, Negi A: Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) 2009; 23: 108-111.
41. Ferris F: Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996; 94: 505-537. (Pubitemid 26406045)